Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cyclosporin+ mycophenolate mofetil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cyclosporin + Mycophenolate mofetil | ACTIVE_COMPARATOR | - |
| Everolimus + mycophenolate mofetil | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| cyclosporin + mycophenolate mofetil | DRUG | antirejection drug, renal transplantation |
| everolimus + mycophenolate mofetil | DRUG | antirejection drug, renal transplantation |
Inclusion Criteria: * Males and Females aged between 18 and 70. * Patient receiving a first or second kidney transplant from a deceased donor, living related or unrelated. * Patient with a maximum PRA \<20%. * Patient wishing and being able to participate fully to the study, and having given a writ...
Cyclosporin + mycophenolate mofetil is used for kidney failure, specifically in the context of renal transplantation. It is a combination of two small molecule immunosuppressants being studied to compare the efficacy and safety of a calcineurin inhibitor (CNI) versus a CNI-free treatment regimen in kidney transplant patients.
Cyclosporin + mycophenolate mofetil is developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical research on this combination therapy for kidney failure patients undergoing renal transplantation.
Cyclosporin + mycophenolate mofetil is in Phase 3 clinical development. It is an investigational combination therapy for kidney failure and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug remains under clinical investigation.
Cyclosporin + mycophenolate mofetil was studied in a single Phase 3 clinical trial, NCT01595984, titled 'Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI) Versus a CNI-free Treatment in Renal Transplantation (CIME)'. This completed trial enrolled 88 participants in France and was active-controlled, randomized, and biomarker-selected.
No, cyclosporin + mycophenolate mofetil is not the same as a CNI-free treatment. The combination includes cyclosporin, which is a calcineurin inhibitor (CNI). The clinical trial NCT01595984 compares this CNI-containing regimen against a CNI-free treatment to evaluate their relative efficacy and safety in renal transplantation.